Journal of International Obstetrics and Gynecology ›› 2013, Vol. 40 ›› Issue (4): 339-342.

• 综述 • Previous Articles     Next Articles

Advances in the Medical Treatment of Uterine Leiomyomas Fibroids

ZHANG Hui-ying, XUE Feng-xia   

  1. Department of Obstetrics and Gynecology, Tianjin Medical University General Hospital, Tianjin 300052, China
  • Received:1900-01-01 Revised:1900-01-01 Published:2013-08-15 Online:2013-08-15

Abstract: Uterine leiomyoma is the most common benign tumor of female reproductive system, which approximately 20% of women during reproductive years suffer from. Some patients are asymptomatic, while some suffer from severe anemia because of menorrhagia. As for treatment, surgery is the preferred solution for radical cure. However, due to the patients′ age and different fertility requirement, some patients do not want surgery, and some are not suitable for operation. Then gonadotropin-releasing hormone agonists and other drugs such as mifepristone can help reduce estrogen levels to inhibit the growth of myoma, and to make the myoma shrink, so as to improve clinical symptoms, which is one of another important treatments for uterine leiomyoma.

Key words: Uterus, Leiomyoma, Drug therapy, Gonadotropin-releasing hormone, Gonadotropin-releasing hormone agonists, Selective progesterone receptor modulators